Actinium Pharmaceuticals (ATNM) investor relations material

Executive summary

• Annual Meeting scheduled for Nov. 25, 2026; stockholders of record on Oct. 2, 2026 may vote, with one vote per common share.

• Board unanimously recommends FOR both director nominees, CBIZ auditor ratification and the advisory say-on-pay proposal.

Voting matters and shareholder proposals

• David Nicholson and Richard I. Steinhart are nominees for Class I, three-year terms ending at the 2029 Annual Meeting; election is by plurality.

• CBIZ CPAs P.C. appointment for FY ending Dec. 31, 2026 requires a majority of shares present and entitled to vote; abstentions and broker non-votes count against.

• Say-on-pay covers NEO compensation for FY ended Dec. 31, 2025; approval requires a majority of shares present and entitled to vote, and broker non-votes have no effect.

• Rule 14a-8 proposals for the 2027 meeting are due by June 17, 2027; director nominations for the proxy card under Rule 14a-19 are due by Sept. 26, 2027.

Board of directors and corporate governance

• Six directors serve on a classified board; five are deemed independent under NYSE American standards.

• Sandesh Seth combines Board Chair and CEO roles; David Nicholson serves as lead independent director and chairs independent-director executive sessions.

• Board held six meetings in 2025; each director attended at least 75% of applicable Board and committee meetings.

• Audit, Compensation, and Nominating and Corporate Governance committees are standing committees; committee chairs are independent directors.